A cyclometalated iridium(III) complex that induces apoptosis in cisplatin-resistant cancer cells

被引：5
作者：
Wang, Jin-Quan [1 ]
Hou, Xiao-Juan [2 ]
Bo, Hua-Ben [1 ]
Chen, Qi-Zhu [1 ]
机构：
[1] Guangdong Pharmaceut Univ, Guangdong Prov Key Lab Biotechnol Candidate Drug, Guangzhou 510006, Guangdong, Peoples R China
[2] Huaihua Med Coll, Huaihua 418000, Peoples R China
来源：
INORGANIC CHEMISTRY COMMUNICATIONS | 2015年 / 61卷
基金：
中国国家自然科学基金;
关键词：
Iridium(III) complex; Platinum resistance; ROS; NF-kappa B; Apoptosis; LUNG ADENOCARCINOMA; CHEMORESISTANCE;
D O I：
10.1016/j.inoche.2015.08.013
中图分类号：
O61 [无机化学];
学科分类号：
070301 ; 081704 ;
摘要：
A novel cyclometalated iridium(Ill) complex, [Ir(C boolean AND N)(2)(HPIP)]Cl (IrC) was synthesized and characterized. IrC exhibited about 10-fold higher cytotoxicity than cisplatin against A549 cancer cell line. Interestingly, a cisplatin-resistant cell line, A549-CP/R showed sensitivity to IrC. Further study suggested that IrC induced apoptosis via negatively regulated the nuclear factor-kappa B (NF-kappa B) pathway, which involved reactive oxygen species (ROS) generation, Bd-2 and caspase family members activation. Taken together, these results suggest that IrC is able to overcome chemoresistance and may be an effective treatment for platinum-resistant cancer therapy. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码：31 / 34
页数：4
相关论文
共 12 条
  • [1] New trends for metal complexes with anticancer activity
    Bruijnincx, Pieter C. A.
    Sadler, Peter J.
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2008, 12 (02) : 197 - 206
  • [2] MnSOD overexpression confers cisplatin resistance in lung adenocarcinoma via the NF-κB/Snail/Bcl-2 pathway
    Chen, Po-Ming
    Cheng, Ya-Wen
    Wu, Tzu-Chin
    Chen, Chih-Yi
    Lee, Huei
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 2015, 79 : 127 - 137
  • [3] Cellular Selectivity and Biological Impact of Cytotoxic Rhodium(III) and Iridium(III) Complexes Containing Methyl-Substituted Phenanthroline Ligands
    Geldmacher, Yvonne
    Kitanovic, Igor
    Alborzinia, Hamed
    Bergerhoff, Katharina
    Rubbiani, Riccardo
    Wefelmeier, Pascal
    Prokop, Aram
    Gust, Ronald
    Ott, Ingo
    Woelfl, Stefan
    Sheldrick, William S.
    [J]. CHEMMEDCHEM, 2011, 6 (03) : 429 - 439
  • [4] Phosphorescent iridium(III)-bis-N-heterocyclic carbene complexes as mitochondria-targeted theranostic and photodynamic anticancer agents
    Li, Yi
    Tan, Cai-Ping
    Zhang, Wei
    He, Liang
    Ji, Liang-Nian
    Mao, Zong-Wan
    [J]. BIOMATERIALS, 2015, 39 : 95 - 104
  • [5] Organometallic Iridium(III) Cyclopentadienyl Anticancer Complexes Containing C,N-Chelating Ligands
    Liu, Zhe
    Habtemariam, Abraha
    Pizarro, Ana M.
    Clarkson, Guy J.
    Sadler, Peter J.
    [J]. ORGANOMETALLICS, 2011, 30 (17) : 4702 - 4710
  • [6] Organometallic Half-Sandwich Iridium Anticancer Complexes
    Liu, Zhe
    Habtemariam, Abraha
    Pizarro, Ana M.
    Fletcher, Sally A.
    Kisova, Anna
    Vrana, Oldrich
    Salassa, Luca
    Bruijnincx, Pieter C. A.
    Clarkson, Guy J.
    Brabec, Viktor
    Sadler, Peter J.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (08) : 3011 - 3026
  • [7] Dinuclear organoiridium(III) mono- and bis-intercalators with rigid bridging ligands: Synthesis, cytotoxicity and DNA binding
    Nazif, Mhd. Ali
    Bangert, Jan-Amade
    Ott, Ingo
    Gust, Ronald
    Stoll, Raphael
    Sheldrick, William S.
    [J]. JOURNAL OF INORGANIC BIOCHEMISTRY, 2009, 103 (10) : 1405 - 1414
  • [8] Stölting DP, 2014, ANTICANCER RES, V34, P525
  • [9] Synthesis, structures, cellular uptake and apoptosis-inducing properties of highly cytotoxic ruthenium-Norharman complexes
    Tan, Caiping
    Wu, Shouhai
    Lai, Sensen
    Wang, Minxu
    Chen, Yu
    Zhou, Lingjun
    Zhu, Yiping
    Lian, Wu
    Peng, Wenlie
    Ji, Liangnian
    Xu, Anlong
    [J]. DALTON TRANSACTIONS, 2011, 40 (34) : 8611 - 8621
  • [10] Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
    Trachootham, Dunyaporn
    Alexandre, Jerome
    Huang, Peng
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (07) : 579 - 591
12